Iavarone M, Perrino M, Vigano M, Beck-Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid. 2010;20(9):1043–4.
Article
CAS
PubMed
Google Scholar
van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197–202.
Article
PubMed
Google Scholar
Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69(4):669–72.
Article
CAS
Google Scholar
Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008;19(2):265–8.
Article
CAS
PubMed
Google Scholar
Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010;28(5):515–9.
Article
CAS
PubMed
Google Scholar
Konca Degertekin C, Coskun U, Balos Toruner F, Akturk M, Demirci U. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer. Endocrine. 2012;42(3):756–7.
Article
CAS
PubMed
Google Scholar
Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, Braun D, Schweizer U, Arnold R, Dorken B, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20(11):1209–14.
Article
CAS
PubMed
Google Scholar
de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005;78(4):433–8.
Article
PubMed
Google Scholar
de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466–9.
Article
PubMed
Google Scholar
Babacan T, Sevinc A, Akarsu E, Balakan O. Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report. Chemotherapy. 2012;58(2):142–5.
Article
CAS
PubMed
Google Scholar
Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145(9):660–4.
Article
PubMed
Google Scholar
Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81–3.
Article
CAS
PubMed
Google Scholar
Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(9):3531–4.
Article
CAS
PubMed
Google Scholar
Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160(3):331–6.
Article
CAS
PubMed
Google Scholar
Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, Oki Y, Ozono S, Nakamura H. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid. 2013;23(4):443–8.
Article
CAS
PubMed
Google Scholar
Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42(8):742–7.
Article
PubMed
Google Scholar
Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42.
Article
CAS
PubMed
Google Scholar
Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol Med. 2005;11(9):397–402.
Article
CAS
PubMed
Google Scholar
Seggewiss R, Price DA, Purbhoo MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy. 2008;10(6):633–41.
Article
CAS
PubMed
Google Scholar
Seliger B, Massa C, Rini B, Ko J, Finke J. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med. 2010;16(4):184–92.
Article
CAS
PubMed
Google Scholar
Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved? Thyroid. 2015;25:11.
Article
Google Scholar